NasdaqGM - Delayed Quote USD

Wave Life Sciences Ltd. (WVE)

Compare
6.23 -0.25 (-3.86%)
At close: June 14 at 4:00 PM EDT
6.14 -0.09 (-1.44%)
After hours: June 14 at 7:22 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Paul B. Bolno M.B.A., M.D. President, CEO & Director 1.13M -- 1974
Mr. Kyle B. Moran CFA CFO & Principal Accounting Officer 726.34k -- 1971
Dr. Chandra Vargeese Ph.D. Chief Technology Officer 731.8k -- 1961
Dr. Erik Ingelsson M.D., Ph.D. Chief Scientific Officer -- -- --
Kate Rausch Head of Investor Relations -- -- --
Ms. Linda Rockett J.D. Senior VP & General Counsel -- -- --
Dr. Christopher Francis Ph.D. Senior VP of Corporate Development & Head of Emerging Areas 493.13k 4.75M 1978
Ms. Daryn Lewis Senior VP & Head of Human Resources -- -- --
Dr. Sridhar Vaddeboina Ph.D. Senior Vice President of Chemistry, Manufacturing & Controls -- -- --
Ms. Anne-Marie Li-Kwai-Cheung Chief Development Officer -- -- --

Wave Life Sciences Ltd.

Marina One East Tower
7 Straits View No.12-00
Singapore, 018936
Singapore
65 6236 3388 https://www.wavelifesciences.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
266

Description

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Corporate Governance

Wave Life Sciences Ltd.’s ISS Governance QualityScore as of June 1, 2024 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 3; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 1, 2024 at 12:30 PM UTC - August 5, 2024 at 12:30 PM UTC

Wave Life Sciences Ltd. Earnings Date

Recent Events

May 10, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 29, 2024 at 12:00 AM UTC

10-K/A: Periodic Financial Reports

April 11, 2024 at 12:45 PM UTC

at Needham Virtual Healthcare Conference

April 3, 2024 at 7:10 PM UTC

at Cantor Fitzgerald Muscular Dystrophy Symposium (Virtual)

March 6, 2024 at 1:30 PM UTC

Q4 2023 Earnings Call

March 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 15, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers